MDT-AP-3303
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 9.5
- sex
- M
- new_clusters
- C3
- umap1_2d
- 5.24418137
- umap2_2d
- 4.056074893
- umap1_3d
- 2.46834924
- umap2_3d
- -2.494965795
- umap3_3d
- -3.647245134
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.390
- UV_RESPONSE_DN+0.250
- ANDROGEN_RESPONSE+0.210
- WNT_BETA_CATENIN_SIGNALING+0.180
- TGF_BETA_SIGNALING+0.160
- HEME_METABOLISM+0.140
- MITOTIC_SPINDLE+0.130
- PEROXISOME+0.110
- ADIPOGENESIS+0.100
- OXIDATIVE_PHOSPHORYLATION+0.080
Top 10 suppressed
- E2F_TARGETS-0.420
- IL6_JAK_STAT3_SIGNALING-0.340
- ANGIOGENESIS-0.310
- COAGULATION-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.290
- UV_RESPONSE_UP-0.280
- G2M_CHECKPOINT-0.260
- CHOLESTEROL_HOMEOSTASIS-0.250
- KRAS_SIGNALING_DN-0.250
- ESTROGEN_RESPONSE_LATE-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3290 | Med | Medulloblastoma | 0.848 |
| 2 | MDT-AP-3246 | Med | Medulloblastoma | 0.838 |
| 3 | MDT-AP-3271 | Med | Medulloblastoma | 0.834 |
| 4 | SRR1516042 | — | — | 0.833 |
| 5 | MDT-AP-3296 | Med | Medulloblastoma | 0.831 |
| 6 | MDT-AP-3253 | Med | Medulloblastoma | 0.812 |
| 7 | R357 | — | — | 0.808 |
| 8 | BS_Z7PKVY9J | Med | Medulloblastoma | 0.806 |
| 9 | TCGA-44-6146-01A-11R-A278-07 | — | cohortA1 | 0.787 |
| 10 | TCGA-44-5645-01A-01R-A278-07 | — | cohortMD2 | 0.783 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.130 | Inavolisib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.080 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.040 | Inavolisib | — uncovered |